Radiopharmaceuticals market Report 2025: Trends, Growth, and Key Players Forecast to 2035 | GE Healthcare , Siemens Healthineers, Cardinal Health, Bayer AG , Eli Lilly and Company

The Radiopharmaceuticals market accounted for USD 6.75 Billion in 2024 and is expected to reach USD 16.48 Billion by 2035, growing at a CAGR of around 8.45% between 2025 and 2035. The radiopharmaceuticals market is the industry involved in producing and applying radioactive medicinal substances for treatment. Most applications of radiopharmaceuticals are in diagnostics and therapy, with compounds referred to as radiotracers or radiolabeled drugs.
These compounds are used in techniques such as PET and SPECT to detect and treat cancer cardiovascular diseases and neurological disorders. All of these facets drive growth within the market such as advancing imaging technology, increasing cases of chronic diseases, and increasing awareness regarding personalized medicine. The global market for radiopharmaceuticals is growing, and advancements in both diagnosis and therapy radiopharmaceuticals fuel this. Regulatory challenges and radiation safety issues remain a drag on the market growth curve.

Get a Sample Copy of This Report
@ https://www.metatechinsights.com/request-sample/1409

"I am honoured to join NUCLIDIUM at this pivotal moment on its journey. The company's innovative copper-based radiopharmaceutical platform holds significant promise for advancing precision oncology. I look forward to collaborating with the board and leadership team to drive the development of targeted cancer diagnostics and therapies that can make a meaningful impact on patient care."
• Tony Rosenberg, Chairman-Elect of the NUCLIDIUM Board
"To reach their full potential as treatments for millions of patients with limited options, theranostic radiopharmaceuticals must be available close to those who need them."
• Charles S. Conroy, CEO of Nucleus RadioPharma

Segment Analysis
1. Market Type:
2. The radiopharmaceuticals market is divided into diagnostic and therapeutic segments. The diagnostic segment leads, driven by the demand for PET and SPECT imaging in early diagnosis, especially for cancer, heart, and neurological diseases.
3. Radioisotope:
4. Key radioisotopes include Technetium-99m, Fluorine-18, and Iodine-131, with Technetium-99m dominating due to its ideal properties for diagnostic imaging in SPECT, offering low radiation exposure and high-quality images for a wide range of conditions.

Regional Analysis:
• North America leads the market, with high demand for radiopharmaceuticals driven by advanced healthcare infrastructure and high disease incidence.
• Asia-Pacific is the fastest-growing region, fueled by improving healthcare, rising cancer awareness, and government support, particularly in China, India, and Japan.

Competitive Landscape:
Key players like GE Healthcare, Siemens Healthineers, and Lantheus Medical Imaging are innovating with new diagnostic agents and systems. Lantheus, for example, recently gained approval for a prostate cancer imaging agent, enhancing its oncology portfolio.


Report Coverage:
By Type
• Diagnostic
• SPECT
• PET
• Others
• Therapeutic
• Alpha Emitters
• Beta Emitters
• Neutron Capture Therapy (NCT)
• Others
By Radioisotope
• Technetium-99m
• Fluorine-18
• Iodine-131
• Lutetium-177
• Gallium-68
• Others
By Application
• Oncology
• Cardiology
• Neurology
• Orthopedics
• Infectious Diseases
• Others
By Source
• Nuclear Reactors
• Cyclotrons
By End-user
• Hospitals
• Diagnostic Imaging Centers
• Cancer Treatment Centers
• Research Institutions
By Region
North America
• U.S.
• Canada
Europe
• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific
Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC Countries
• South Africa
• Rest of the Middle East & Africa

Get a Customization Report
@ https://www.metatechinsights.com/customize-report/1409

Leading key players
• GE Healthcare
• Siemens Healthineers
• Cardinal Health
• Bayer AG
• Eli Lilly and Company
• Novartis
• Thermo Fisher Scientific
• United Radiopharmaceuticals
• Telix Pharmaceuticals
• Lantheus Medical Imaging
• NorthStar Medical Radioisotopes
• Advanced Accelerator Applications (AAA)
• Isologic Innovative Radiopharmaceuticals
• Bracco Imaging
• Ion Beam Applications (IBA)


Inquiry Before Buying
@ https://www.metatechinsights.com/inquiry-before-buying/1409

Frequently Asked Questions (FAQs)
What is the Radiopharmaceuticals Market size in 2024 and how will it evolve through 2035?
What are the key growth opportunities in the Radiopharmaceuticals Market?
Which are the largest and fastest-growing segments in the Radiopharmaceuticals Market?
Which region will make a notable contribution to the Global Radiopharmaceuticals Market?
Who are the leading players operating in the global Radiopharmaceuticals Market?

Address :
50 MacAleese Lane #24, Moncton, New Brunswick, E1A 3L9, Canada

Contact Us:
Web: www.metatechinsights.com
Ph: US - +1 5064 048 481
Email: sales@metatechinsights.com

About Us:
Metatech Insights specializes in making comprehensive global and regional market research reports in Healthcare, Medical Devices, Healthcare IT, Agriculture, Chemicals and Materials, Consumer Goods, Food & Beverages, Pet Care, Cryptocurrency, and Novel technologies. Our meticulously designed research reports are regarded as one of the most detailed and well-thought market research studies available in the industry. Our reports typically include market assessments, analysis of industry trends, and competitive intelligence.

This release was published on openPR.